Introduction
Heart failure (HF) is associated with considerably high rates of mortality and morbidity.
1, 2 The aetiology and pathophysiology of HF show substantial interindividual heterogeneity. [3] [4] [5] Nevertheless, patients with HF are uniformly treated according to guidelines with angiotensin-converting enzyme-inhibitors (ACEi) and beta-blockers. 6, 7 Distinguishing relevant disease subtypes within the spectrum of patients with HF is imperative to create a better understanding of the underlying pathophysiology as well as to identify subgroups of patients not benefiting from available treatment options. Clustering algorithms are frequently used to identify subgroups. Clustering methods try to identify mutually exclusive subgroups based on a set of variables. Recently, Ahmad et al. 4 showed distinct disease phenotypes with differing outcomes by using a cluster-based approach. However, the use of clinical characteristics as the basis for subgroup determination has been criticized, since this will yield naturally occurring clusters of signs and symptoms and not distinct disease subtypes. 8 The advantage of using biomarker profiles over clinical characteristics to determine cluster membership, is that it enables us to possibly identify patients who phenotypically look the same, yet might respond differently to guideline directed medication based on their underlying biomarker profile. Therefore, we aimed to identify mutually exclusive subtypes of HF patients based on biomarker profiles using a wide range of cardiovascular biomarkers, which can provide new insights into the heterogeneity of HF. These endotypes are then compared with regards to their characteristics, clinical outcome, and their benefit/harm to uptitration of ACEi/angiotensin receptor blockers (ARBs) and/or beta-blockers.
Methods

Patient population
This study utilized patients from the BIOSTAT-CHF project, which is described elsewhere. 9 In short, the BIOSTAT-CHF study includes two cohorts of patients with HF. The index cohort consists of 2516 patients with HF from 69 centres in 11 European countries. Inclusion criteria for the index cohort include: patients with >18 years of age, having symptoms of new-onset or worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of < _40% or B-type natriuretic peptide (BNP) and/or N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels >400 pg/mL or >2000 pg/mL, respectively. Patients had not been previously treated with an ACEi/ARBs and/or beta-blocker or they received < _50% of ACEi/ARB and/or beta-blockers at the time of inclusion and anticipated initiation/uptitration of ACEi/ARBs and beta-blockers. The validation cohort includes 1738 patients from six centres in Scotland, UK. Patients were required to be > _18 years of age, diagnosed with HF and were previously admitted with HF requiring diuretic treatment. They were sub-optimally treated with ACEi/ARBs and/or betablockers, and anticipated initiation or uptitration of ACEi/ARBs and betablockers. Patients in both cohorts could be enrolled as inpatients or from out-patient clinics. 9 Of the 2516 patients included in the index cohort, we excluded 151 patients who died and 23 patients who were censored before 3 months follow-up. Additionally, we excluded 242 patients with LVEF > 40%. Of the remaining 2100 patients, there were 298 patients with missing values on the biomarkers. Subsequent analyses were done with data from the remaining 1802 patients. 10 Findings were validated in 813 patients with LVEF < _40% and biomarker measurements available in the validation cohort.
Clinical measurements and definitions
Medical history, medication use, and physical examination were recorded at baseline. Changes in ACEi/ARBs and beta-blockers were recorded. Investigators were expected to optimize treatment within the first 3 months. Patients were considered successfully uptitrated when recommended dose for either ACEi/ARB or beta-blocker was achieved after 3 months of uptitration according to current ESC guidelines. 6 The achieved dose was defined as the highest dose achieved within the uptitration period in percentage of the recommended treatment dose for either ACEi/ARB or beta-blocker.
Outcome analyses
To investigate possible differences between endotypes and outcome, we used a combined the combined outcome of all-cause mortality and HF hospitalizations at 2 years. Hospitalizations due to HF were determined by the investigator. We investigated whether a difference in treatment response could be observed between endotypes. Treatment response is defined as the survival benefit of successful uptitration to guideline directed target dosages for the combined outcome.
Biomarker measurements
An overview of biomarkers and their pathophysiological function are presented in Supplementary material online, platform. The platform provides normalized protein expression (NPX, log2-normalized), but not an absolute quantification. In total, 98.4% of measurements were within range, 1.6% of measurements were below the lower limit of detection (LOD). These were replaced by the LOD, which was found reasonable when having less than 10% of measurements below the LOD. 11, 12 Characteristics of the biomarker assay are presented in Supplementary material online, Table S2 .
Statistical analysis
We have provided a comprehensive explanation of the statistical methods used in the Supplementary material online. In brief, the primary analytical goal of this study is to identify mutually exclusive subgroups of patients (clusters) based on their biomarker profile using 92 biomarkers, which we have called endotypes. Biomarker dimensions were reduced by performing principal component analysis (PCA). The optimal number of clusters in our analyses was determined using the package NBclust in R.
The package NBclust uses a wide array of different measures to select the optimal number of clusters in a given dataset. Following, the number of cluster most often selected throughout is then selected as the optimal number of clusters for the analyses. 13 We have used k-nearest neighbors to validate our findings. 3, [14] [15] [16] Cluster membership in the validation cohort was determined by first projecting the results of the PCA on the biomarker in the validation cohort, followed by the calculation of the nearest cluster, using k-nearest neighbors in the index cohort, for each patient in the validation cohort. [14] [15] [16] Differences between clinical characteristics of endotypes were compared using one-way analysis of covariance (ANOVA) 
Kruskal-Wallis test, or the v
2 test where appropriate. Differences of biomarkers means between endotypes were plotted using a heatmap after z-standardization of biomarker means to make them comparable. The Cindex for the three biomarkers with the lowest P-value for association with individual clusters were assessed. The association with the primary outcome was investigated using Kaplan-Meier curves and the log-rank test. For multivariable analyses, Cox regression analysis was performed, correcting for relevant clinical confounders and the BIOSTAT risk model, which was previously published. 17 The BIOSTAT risk model for predicting mortality included, age, blood urea nitrogen (BUN), N-terminal NT-proBNP, haemoglobin, and the use of a beta-blocker at time of inclusion. The BIOSTAT risk model for predicting mortality or HF hospitalization included age, NT-proBNP, haemoglobin, the use of a beta-blocker at time of inclusion, a HFhospitalization in year before inclusion, peripheral oedema, systolic blood pressure, high-density lipoprotein cholesterol, and sodium. The association between endotypes and uptitration rates of ACEi/ ARBs and beta-blockers to recommended target doses was investigated using logistic regression and corrected for the previously published uptitration models from the BIOSTAT cohort. 18 For ACEi/ARB this model includes sex, body mass index (BMI), estimated glomerular filtration rate (eGFR), alkaline phosphate, and country. For beta-blockers, this model included age, country of origin, diastolic blood pressure, heart rate, and pulmonary congestion at baseline. Additionally, we have corrected for important clinical confounder including ischaemic aetiology, potassium levels, and use of MRAs at time of inclusion. To investigate a difference in treatment benefit of being uptitrated to guideline directed medication levels during follow-up, we performed interaction analysis between endotype membership and being uptitrated to > _100% of guideline recommended dosages (yes vs. no) or ACEi/ARB or beta-blockers. To adjust for treatment-indication bias, risk estimates for the primary endpoint for successful uptitration of ACEi/ARB and beta-blockers were adjusted using inverse probability weighting using 55 clinical and laboratory variables (Supplementary material online, Table S3 ).
Results
Clustering outcomes
The optimal number of clusters was 6, ranging from a minimum of 80 to a maximum of 435 patients (Supplementary material online, Figure  S2 ). Heatmaps of biomarkers across endotypes for the index and validation cohort are depicted in Figure 1 , and C-indexes of the top three significantly associated biomarkers per endotype presented in Table 1 (validation in Supplementary material online, Table S4 ). Overall, a limited number of biomarkers identified endotype membership with a relatively high C-index (> _0.78; Table 1 ). Patients with endotype 5 had very low levels of chitotriosidase 1 (CHIT1).
Clinical characteristics
Baseline characteristics of subgroups are presented in Table 2 . Patients with endotype 1 were youngest, more often in New York Heart Association (NYHA) Class I/II (58%) and had relatively mild signs and symptoms compared with patients with other endotypes. Patients with endotype 1 had the lowest rates of anaemia and lowest NT-proBNP levels. Patients with endotype 2 had the higher rates of anaemia (45.1%) and high rates of CKD (65.4%) compared with other endotypes (P < 0.001). Patients with endotype 3 most often had an ischaemic aetiology of HF. Patients with endotype 4 had the worst signs and symptoms and highest NT-proBNP levels. Patients with endotype 5 had relatively high rates of anaemia (40%). Patients with endotype 6 had the highest rates of hypertension (66%). A summary of clinical characteristics per endotype is provided in Supplementary material online, Figure S1 .
Outcome
After a median follow-up of 21 months, (34%) patients either had a hospitalization for HF or died. Event rate was highest in endotype 4 After correction for the BIOSTAT-CHF risk models, endotype 4 had worse outcomes compared with endotype 1 for the combined outcome, while endotypes 2 and 4 had higher rates of mortality alone ( Table 3 ; Supplementary material online, Table S5 ). Compared with the BIOSTAT-CHF risk model (C-index 0.71), the classification into endotypes performed worse (C-index 0.61). Interestingly, the BIOSTAT-CHF risk model performed worse in endotypes 2, 3 and 4 (C-index 0.64) and better in endotypes 6 (C-index 0.75; Supplementary material online, Table S6 ).
Uptitration of HF medication to guideline directed dosages and treatment response
Overall rates of uptitration to recommended target dose of ACEi/ ARBs were lowest in endotype 4 and highest in endotypes 3 and 6 ( Figure 3A) . Significantly less benefit was observed for uptitration of ACEi/ARB uptitration for endotype 5 (HR 1.29; 95% CI 0.88-1.88) for the primary combined outcome ( Figure 3B , Supplementary material online, Table S7 , P interaction <0.001).
Beta-blocker uptitration rates was lowest in endotype 6 and highest in endotypes 1 and 5, also after correction for ACEi/ARB uptitration rates (P < 0.01, Figure 3C ). Endotype 6 derived more benefit from successful uptitration on beta-blockers for the combined outcome. In contrast, endotype 2 (HR 1.29; 95% CI 1.10-1.52) had a negative treatment response to beta-blocker uptitration, while endotype 5 did not seem to derive any benefit ( Figure 3D , Supplementary material online, Table S7 , P interaction <0.001).
Validation
Patients in the validation cohort were older with lower NT-proBNP levels, other characteristics were generally comparable between both cohorts (Supplementary material online, Table S8 ).
Overall, the results of the cluster analysis were remarkably similar between the index and the validation cohort. Particularly the relative differences between clusters were well validated between cohorts. Figure 1 shows the marked similarity in the biomarker profiles between both cohorts. Supplementary material online, Table S9 shows the great similarity in clinical characteristics of the six endotypes between both the index and validation cohorts. Figure 2 shows the remarkable similarity in clinical outcome: endotype 4 had the worst outcomes and patients with endotype 1 had the best outcomes of all endotypes.
Discussion
Using sophisticated classification techniques based on biomarker profiles, novel mutually exclusive subgroups in HF were identified and validated in an independent cohort. We found striking differences between endotypes in terms of mortality and/or HF hospitalization, uptitration rates of guideline-directed medication, and treatment response. These data show that when classifying patients based on biomarker profiles, specific subgroups with a heterogeneous clinical profile emerge. These specific 'endotypes' are not only different in terms of their clinical profile, but also with regards to clinical outcome and their response to uptitration of ACEi/ARB and betablockers. This is the first study using a large panel of biomarkers to identify subgroups in HF.
Previous studies in HF identified subgroups via cluster analysis using clinical characteristics, echocardiographic variables and laboratory data.
3,4 A study by Ahmed et al. 4 found novel subgroups in patients with HFrEF using clinical characteristics, however, it was suggested that this study potentially identified subgroups based on disease severity and not actual subtypes based on differences in underlying disease mechanisms. Of note, Shah et al. 3 identified phenotypes of patients with HFpEF using clinical characteristics, echocardiographic parameters, and laboratory data, which could reflect underlying pathophysiological differences more directly. This study solely used biomarker profiles for defining subgroups in HF using a comprehensive set of biomarkers reflecting a greater number of disease domains. The dynamic state of biomarkers suggests that not all biomarker levels reflect a consistent biological response, but instead a snapshot of the biological processes at that time point. Here, PCA can reclassify biomarkers into individual biological processes, which reduces the dynamic effect of individual biomarkers. 19, 20 Future studies should focus on parameters reflecting a more consistent biological response. A potential strength of using biomarker profiles to reclassify patients with HF, is that we were able to identify patients with a specific endotype, who might have a non-remarkable phenotype based on clinical variables but respond differently to guidelinedirected treatment. An important case-in-point of this, is endotype 2.
Patients with this endotype did not show a strong phenotype, yet these patients seemingly did not derive treatment benefit from betablockers treatment at guideline directed levels. The six endotypes identified had a distinct biomarker profile and phenotype. A possible important difference was observed for patients with endotype 1 (best outcomes) and patients with endotype 4 (worst outcomes). Patients with endotype 1 had very low levels of IGFBP1 and NT-proBNP, while patients with endotype 4 had very high levels of IGFBP1 and NT-proBNP. The very low levels of CHIT1 found in patients with endotype 5 were striking. CHIT1, part of a family of hydrolyzing enzymes, is active in both pathophysiological as well as in physiological circumstances. 21 Increased levels of CHIT1 are associated with arteriosclerosis and Gaucher's disease, furthermore 10-25% of European populations are CHIT1 deficient due to a genetic polymorphism. 22 126 (22) 122 (23) 127 (19) 119 (21) 125 (23) 127 (19) <0.001
Diastolic BP (mmHg) 77 (13) 73 (14) 77 (12) 74 (13) 76 (16) 76 (12) <0.001 LVEF (%) 29 (7) 28 (8) 29 (8) 26 (8) 28 (8) 30 (7) <0.001 Heart rate (b.p.m.)
83 (22) 80 (20) 77 (16) 84 (21) 81 (17) 75 (17) <0.001
Signs and symptoms (%) (2) 13 (2) 14 (2) 13 (2) 13 (2) 13 ( deficient for CHIT1 and constituted roughly 4% of the patients in this index cohort. This suggest that CHIT1 might be an interesting novel target, which deserved further study. A limited number of biomarkers could adequately discriminate patient endotype membership with a high C-index. This suggests that in a clinical setting, a patient's endotype membership can be determined by measuring a relatively small number of biomarkers. While promising, more work needs to be done to increase clinical feasibility and cost-effectiveness of this method. While endotype membership was an independent predictor of outcome, the overall goal of cluster analysis and this study was not to provide a novel prediction model based on endotypes. There are more advanced techniques to improve risk stratification using both unsupervised as well as supervised techniques, including neural network analysis and support vector machine. 23 Instead, the goal of this study was to provide for a novel classification of HF patients by identifying mutually exclusive subgroups based on biomarker profiles. These subgroups can then potentially be used to optimize risk stratification. Indeed, our results show that there are clear differences in the C-index of the BIOSTAT-CHF risk model between subgroups. 17 Hence, (re-)classification of patients with HF, might improve risk stratification using existing risk prediction models. There were marked differences in the uptitration rates of ACE/ ARB and beta-blockers, particularly patients with endotypes 3 and 6 were more often uptitrated to target dose for ACEi/ARB and patients with endotypes 1 and 5 were more often uptitrated to target dose for beta-blockers, independent of confounders. Patients with endotype 2 seemed to derive more benefit of ACEi/ARB uptitration than other endotypes. This is of particular interest given the high rates of CKD in patients with endotype 2. There is a paucity of data on the benefits of ACEi/ARB usage in patients with CKD and HF, due to exclusion of these patients in most randomized controlled trials. [24] [25] [26] [27] Patients with endotype 2 derived potential harm from uptitration to guideline directed dosages of beta-blockers. This suggests that beyond clinical characteristics, the endotype of a patient might determine response to guideline-directed medication. This study has important implications. Firstly, using biomarker profiles to group HF patients leads to potentially clinically meaningful subgroups in HF with differences in uptitration rates as well as treatment benefit of key HF guideline medications independent of confounders. Therefore, patients with similar phenotypes, may respond differently to guideline-directed medication based on their respective endotype, which deserver further study. Furthermore, we observed that subgroup membership could be identified with relatively high Cindexes using single biomarkers. This suggests that in a clinical setting, a small set of biomarkers can be used to identify a patient's subgroup membership.
Limitations
First of all, biomarkers used were part of a cardiovascular disease panel, which might not completely reflect the pathophysiological processes within HF. Secondly, we tried to correct for indication bias by performing inverse-probability-weighting, but it cannot be established whether we corrected sufficiently for indication bias. Additionally, the BIOSTAT-CHF is primarily a Caucasian cohort, extrapolation of results to other ethnicities is unclear. Pharmacological therapy at time of study inclusion might have influenced plasma levels of some biomarkers, which could not be accounted for in the analyses. As per design, information on uptitration was not available in the validation cohort. No absolute biomarker levels were available. Despite rigorous statistical techniques to correct for indication bias, results of this study might be further confounded by indication bias and need to be repeated in a more controlled setting. Lastly, echocardiography was not an entry criterion for the BIOSTAT-CHF and echocardiography was performed within 2 years before baseline.
Conclusions
This is the first study performing a comprehensive cluster analysis in patients with HF based on a large panel of biomarkers Our data suggest that specific pathophysiological profiles, reflected by circulating biomarkers, have a differential impact on clinical outcome and the response to uptitration of ACEi/ARB and beta-blockers. 
